Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.

Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP
J Am Coll Cardiol. 2019 73 (11): 1336-1349

PMID: 30898209 · PMCID: PMC7957366 · DOI:10.1016/j.jacc.2019.01.017

Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer.

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

MeSH Terms (8)

Anticoagulants Atrial Fibrillation Blood Coagulation Clinical Trials as Topic Humans Neoplasms Practice Guidelines as Topic Thromboembolism

Connections (1)

This publication is referenced by other Labnodes entities: